Compare · GLP-1 agonist
Amycretin vs Semaglutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Amycretin | Semaglutide | |
|---|---|---|
| Evidence | 6/10 | 10/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An investigational single-molecule GLP-1 and amylin receptor agonist from Novo Nordisk with eye-catching early-phase weight-loss data, but no completed Phase 3 trials and no approval anywhere. | A GLP-1 drug with strong RCT evidence for weight loss, glucose control, and cutting cardiovascular events in high-risk patients. |
| Full profile → | Full profile → |
Amycretin
Amycretin is an experimental drug from Novo Nordisk. Its early weight-loss numbers have turned heads, which is exactly why it keeps popping up on peptide forums and gray-market menus. It is a single molecule (one compound, not a blend) that switches on two receptors at the same time — the GLP-1…
Semaglutide
Semaglutide is one of the most heavily studied metabolic drugs of the past decade. Unlike most of the compounds we cover here, the human evidence is large, long-running, and consistent. So the honest job is simple: lay out where it holds up and where it doesn't.